Form 4: Director O'Connor Accrues LMAT Dividend Equivalent Rights

Director John James O'Connor reported the accrual of dividend equivalent rights tied to restricted stock and performance share units in Lemaitre Vascular Inc.

Summary

• Director John James O'Connor reported the acquisition of Dividend Equivalent Rights (DERs) on September 4, 2025.
• These DERs are linked to previously granted Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards.
• Each DER is economically equivalent to one share of Lemaitre Vascular Inc. common stock and vests proportionally with the underlying awards.
• The reported acquisitions include 0.4173 DERs from a 12/12/2022 RSU award, 0.4173 DERs from a 12/12/2022 PSU award, 0.7138 DERs from a 12/8/2023 RSU award, 0.8546 DERs from a 12/8/2023 PSU award, and 0.8697 DERs from a 12/6/2024 RSU award.
• Following these transactions, O'Connor directly holds 6.5156, 5.5269, 5.3975, 5.8691, and 2.9094 DERs respectively for these awards.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction filing reporting the accrual of dividend equivalent rights, which is a standard part of compensation and does not indicate significant positive or negative news about the company's operations or financial health.

Positives

• The accrual of Dividend Equivalent Rights indicates that the underlying equity awards (RSUs and PSUs) are active and accruing value, which aligns the director's interests with shareholder value creation.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it is a report of historical insider transactions.

Industry Context

This is a routine insider transaction filing, common across publicly traded companies, particularly in industries like medical devices (Lemaitre Vascular's sector) where equity compensation is a standard component of executive and director remuneration. It reflects the ongoing administration of existing compensation plans.

Comparison to Industry Standards

• The use of Dividend Equivalent Rights (DERs) tied to Restricted Stock Units (RSUs) and Performance Share Units (PSUs) is a standard practice in executive and director compensation across various industries, including the medical device sector.
• The accrual of fractional shares as DERs is typical for dividend equivalents, reflecting the proportional nature of these rights to the underlying equity awards.
• This filing aligns with common corporate governance practices for transparent disclosure of insider equity holdings and changes.

Related Party Transactions

• The reported transactions represent the accrual of dividend equivalent rights as part of Director John James O'Connor's compensation package, which is a standard related-party transaction in the context of executive and director remuneration.

Stakeholder Impact

• Shareholders: The filing indicates continued alignment of director interests with shareholders through equity-based compensation, but it is a routine disclosure with no significant immediate impact on shareholder value.
• Employees, Customers, Suppliers, Creditors: No direct or material impact on these stakeholders is indicated by this routine compensation filing.

Next Steps

• The underlying Restricted Stock Unit (RSU) and Performance Share Unit (PSU) awards will continue to vest according to their original schedules.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of a director's accrual of dividend equivalent rights on existing equity awards. It provides no new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should maintain their current position based on broader company fundamentals and market conditions, as this filing is neutral in its impact.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Transaction, Director Compensation, Dividend Equivalent Rights, Restricted Stock Units, Performance Share Units, Equity Compensation